An investigation of the chest radiographs in a controlled trial of busulphan, cyclophosphamide, and a placebo after resection for carcinoma of the lung.

Stott, H.; Stephens, R.; Fox, Wallace; Simon, George R.; Roy, Denis‐Claude

doi:10.1136/thx.31.3.265

Cited by 15 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, haematological abnormalities were less frequent with cyclophosphamide and seldom persisted after stopping the drug. Finally, none of the patients on busulphan (or cyclophosphamide) developed radiographic evidence of lung changes which could be ascribed to the drug (Stott et al, 1976).…”

Section: Discussionmentioning

confidence: 96%

5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus

Stott¹,

Stephens²,

Fox³

et al. 1976

Br J Cancer

Self Cite

View full text Add to dashboard Cite

Summary.-This report gives the 5-year findings of a double-blind study of longterm cytotoxic chemotherapy as an adjuvant to surgery in patients receiving busulphan or cyclophosphamide for carcinoma of the bronchus compared with a group receiving a placebo. Of 243 patients initially allocated busulphan, 234 cyclophosphamide and 249 placebo, 28%, 27% and 34%0 respectively were alive at 5 years. There were significant associations between mortality from bronchial carcinoma and histological involvement of the resected intrathoracic nodes and the histology of the tumour.Haematological toxicity, especially thrombocytopenia, was frequent and severe in the busulphan series, and low platelet counts continued long after chemotherapy was stopped.

show abstract

Section: Discussionmentioning

confidence: 96%

5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus

Stott¹,

Stephens²,

Fox³

et al. 1976

Br J Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cyclophosphamide and busulfan (Myleran) were compared in a double‐blind, randomized trial in patients with chronic phase chronic myelocytic leukemia (CML) (Table , Study 15) and in a three arm, randomized, placebo controlled study of post‐resection adjuvant chemotherapy for lung carcinoma. The estimate based on actual median dose (Table , Study 15) was chosen rather than the estimate based on planned total dose (Table , Study 16) .…”

Section: Methodsmentioning

confidence: 99%

“…Cyclophosphamide and busulfan (Myleran) were compared in a double-blind, randomized trial in patients with chronic phase chronic myelocytic leukemia (CML) ( [41,42].…”

Section: Exposure Assessmentmentioning

confidence: 99%

The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report from the childhood cancer survivor study

Green

Nolan

et al. 2013

Pediatric Blood & Cancer

362

283

View full text Add to dashboard Cite

BACKGROUND Estimation of the risk of adverse long-term outcomes such as second malignant neoplasms and infertility often requires reproducible quantification of exposures. The method for quantification should be easily utilized and valid across different study populations. The widely used Alkylating Agent Dose (AAD) score is derived from the drug dose distribution of the study population and thus cannot be used for comparisons across populations as each will have a unique distribution of drug doses. METHODS We compared the performance of the Cyclophosphamide Equivalent Dose (CED), a unit for quantifying alkylating agent exposure independent of study population, to the AAD. Comparisons included associations from three Childhood Cancer Survivor Study (CCSS)outcome analyses, receiver operator characteristic (ROC) curves and goodness of fit based on the Akaike’s Information Criterion (AIC). RESULTS The CED and AAD performed essentially identically in analyses of risk for pregnancy among the partners of male CCSS participants, risk for adverse dental outcomes among all CCSS participants and risk for premature menopause among female CCSS participants, based on similar associations, lack of statistically significant differences between the areas under the ROC curves and similar model fit values for the AIC between models including the two measures of exposure. CONCLUSION The CED is easily calculated, facilitating its use for patient counseling. It is independent of the drug dose distribution of a particular patient population, a characteristic that will allow direct comparisons of outcomes among epidemiological cohorts. We recommend the use of the CED in future research assessing cumulative alkylating agent exposure.

show abstract

“…324,359 Table 29 summarizes the adverse events encountered with cyclophosphamide. 352,357,[360][361][362] Table 30 summarizes seven studies of cyclophosphamide for various lung diseases, 324,352,355,357,360,363,364 and Table 31 summarizes one study in which cyclophosphamide was used for nonpulmonary disease but has important information regarding toxicity. 358 3.5.2.1 Toxicity-Hemorrhagic cystitis is seen with cyclophosphamide therapy and can occasionally be severe or fatal.…”

Section: Cyclophosphamidementioning

confidence: 99%

“…A large prospective study using chest radiography in 192 patients receiving cyclophosphamide failed to fi nd any case of lung fi brosis over 5 years. 363 3.5.2.2 Pregnancy Classifi cation-Cyclophosphamide is teratogenic during pregnancy (FDA category D), especially in the fi rst trimester. 370 Development of sterility variably occurs in both men and women during treatment with cyclophosphamide.…”

Section: Lefl Unomidementioning

confidence: 99%

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Baughman

Meyer

Nathanson

et al. 2012

Chest

View full text Add to dashboard Cite

Objectives: Immunosuppressive pharmacologic agents prescribed to patients with diffuse interstitial and infl ammatory lung disease and lung transplant recipients are associated with potential risks for adverse reactions. Strategies for minimizing such risks include administering these drugs according to established, safe protocols; monitoring to detect manifestations of toxicity; and patient education. Hence, an evidence-based guideline for physicians can improve safety and optimize the likelihood of a successful outcome. To maximize the likelihood that these agents will be used safely, the American College of Chest Physicians established a committee to examine the clinical evidence for the administration and monitoring of immunosuppressive drugs (with the exception of corticosteroids) to identify associated toxicities associated with each drug and appropriate protocols for monitoring these agents. Methods: Committee members developed and refi ned a series of questions about toxicities of immunosuppressives and current approaches to administration and monitoring. A systematic review was carried out by the American College of Chest Physicians. Committee members were supplied with this information and created this evidence-based guideline. Conclusions: It is hoped that these guidelines will improve patient safety when immunosuppressive drugs are given to lung transplant recipients and to patients with diffuse interstitial lung disease. CHEST 2012; 142(5):e1S-e111SAbbreviations: ACCP 5 American College of Chest Physicians; ALT 5 alanine aminotransferase; ATG 5 antithymocyte globulin; CHF 5 congestive heart failure; CMV 5 cytomegalovirus; CNI 5 calcineurin inhibitor; COI 5 confl ict of interest; CsA 5 cyclosporin A; FDA 5 US Food and Drug Administration; HBV 5 hepatitis B virus; HMG-CoA 5 b -hydroxy-bmethylglutaryl-coenzyme A; HSP 5 Health and Science Policy Committee; IL2RA 5 IL-2 receptor a ; ILD 5 interstitial lung disease; IPF 5 idiopathic pulmonary fi brosis; ITP 5 idiopathic thrombocytopenia purpura; LAM 5 lymphangioleiomyomatosis; MESNA 5 sodium 2-sulfonylethanesufonate; MPA 5 mycophenolic acid; mTOR 5 mammalian target of rapamycin; PTLD 5 posttransplant lymphoproliferative disease; RCT 5 randomized controlled trial; SIRS 5 systemic infl ammatory response syndrome; TNF 5 tumor necrosis factor; TPMT 5 thiopurine methyltransferase

show abstract

An investigation of the chest radiographs in a controlled trial of busulphan, cyclophosphamide, and a placebo after resection for carcinoma of the lung.

Cited by 15 publications

References 20 publications

5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus

5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus

The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report from the childhood cancer survivor study

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Contact Info

Product

Resources

About